Turning the tide in myelodysplastic/myeloproliferative neoplasms

Michael W.N. Deininger, Jeffrey Tyner, Eric Solary

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive myeloid malignancies recognized as a distinct category owing to their unique combination of dysplastic and proliferative features. Although current classification schemes still emphasize morphology and exclusionary criteria, disease-defining somatic mutations and/or germline predisposition alleles are increasingly incorporated into diagnostic algorithms. The developing picture suggests that phenotypes are driven mostly by epigenetic mechanisms that reflect a complex interplay between genotype, physiological processes such as ageing and interactions between malignant haematopoietic cells and the stromal microenvironment of the bone marrow. Despite the rapid accumulation of genetic knowledge, therapies have remained nonspecific and largely inefficient. In this Review, we discuss the pathogenesis of MDS/MPN, focusing on the relationship between genotype and phenotype and the molecular underpinnings of epigenetic dysregulation. Starting with the limitations of current therapies, we also explore how the available mechanistic data may be harnessed to inform strategies to develop rational and more effective treatments, and which gaps in our knowledge need to be filled to translate biological understanding into clinical progress.

Original languageEnglish (US)
Pages (from-to)425-440
Number of pages16
JournalNature Reviews Cancer
Volume17
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Myelodysplastic Syndromes
Epigenomics
Genotype
Physiological Phenomena
Phenotype
Cellular Microenvironment
Neoplasms
Germ-Line Mutation
Genetic Therapy
Bone Marrow
Alleles
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Turning the tide in myelodysplastic/myeloproliferative neoplasms. / Deininger, Michael W.N.; Tyner, Jeffrey; Solary, Eric.

In: Nature Reviews Cancer, Vol. 17, No. 7, 01.07.2017, p. 425-440.

Research output: Contribution to journalReview article

Deininger, Michael W.N. ; Tyner, Jeffrey ; Solary, Eric. / Turning the tide in myelodysplastic/myeloproliferative neoplasms. In: Nature Reviews Cancer. 2017 ; Vol. 17, No. 7. pp. 425-440.
@article{70706522f4c947a9af53490ef605a5bb,
title = "Turning the tide in myelodysplastic/myeloproliferative neoplasms",
abstract = "Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive myeloid malignancies recognized as a distinct category owing to their unique combination of dysplastic and proliferative features. Although current classification schemes still emphasize morphology and exclusionary criteria, disease-defining somatic mutations and/or germline predisposition alleles are increasingly incorporated into diagnostic algorithms. The developing picture suggests that phenotypes are driven mostly by epigenetic mechanisms that reflect a complex interplay between genotype, physiological processes such as ageing and interactions between malignant haematopoietic cells and the stromal microenvironment of the bone marrow. Despite the rapid accumulation of genetic knowledge, therapies have remained nonspecific and largely inefficient. In this Review, we discuss the pathogenesis of MDS/MPN, focusing on the relationship between genotype and phenotype and the molecular underpinnings of epigenetic dysregulation. Starting with the limitations of current therapies, we also explore how the available mechanistic data may be harnessed to inform strategies to develop rational and more effective treatments, and which gaps in our knowledge need to be filled to translate biological understanding into clinical progress.",
author = "Deininger, {Michael W.N.} and Jeffrey Tyner and Eric Solary",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/nrc.2017.40",
language = "English (US)",
volume = "17",
pages = "425--440",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Turning the tide in myelodysplastic/myeloproliferative neoplasms

AU - Deininger, Michael W.N.

AU - Tyner, Jeffrey

AU - Solary, Eric

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive myeloid malignancies recognized as a distinct category owing to their unique combination of dysplastic and proliferative features. Although current classification schemes still emphasize morphology and exclusionary criteria, disease-defining somatic mutations and/or germline predisposition alleles are increasingly incorporated into diagnostic algorithms. The developing picture suggests that phenotypes are driven mostly by epigenetic mechanisms that reflect a complex interplay between genotype, physiological processes such as ageing and interactions between malignant haematopoietic cells and the stromal microenvironment of the bone marrow. Despite the rapid accumulation of genetic knowledge, therapies have remained nonspecific and largely inefficient. In this Review, we discuss the pathogenesis of MDS/MPN, focusing on the relationship between genotype and phenotype and the molecular underpinnings of epigenetic dysregulation. Starting with the limitations of current therapies, we also explore how the available mechanistic data may be harnessed to inform strategies to develop rational and more effective treatments, and which gaps in our knowledge need to be filled to translate biological understanding into clinical progress.

AB - Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive myeloid malignancies recognized as a distinct category owing to their unique combination of dysplastic and proliferative features. Although current classification schemes still emphasize morphology and exclusionary criteria, disease-defining somatic mutations and/or germline predisposition alleles are increasingly incorporated into diagnostic algorithms. The developing picture suggests that phenotypes are driven mostly by epigenetic mechanisms that reflect a complex interplay between genotype, physiological processes such as ageing and interactions between malignant haematopoietic cells and the stromal microenvironment of the bone marrow. Despite the rapid accumulation of genetic knowledge, therapies have remained nonspecific and largely inefficient. In this Review, we discuss the pathogenesis of MDS/MPN, focusing on the relationship between genotype and phenotype and the molecular underpinnings of epigenetic dysregulation. Starting with the limitations of current therapies, we also explore how the available mechanistic data may be harnessed to inform strategies to develop rational and more effective treatments, and which gaps in our knowledge need to be filled to translate biological understanding into clinical progress.

UR - http://www.scopus.com/inward/record.url?scp=85021154636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021154636&partnerID=8YFLogxK

U2 - 10.1038/nrc.2017.40

DO - 10.1038/nrc.2017.40

M3 - Review article

C2 - 28642604

AN - SCOPUS:85021154636

VL - 17

SP - 425

EP - 440

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 7

ER -